InhibitorSelect IGF Signaling Pathway Inhibitor Panel

A panel containing 13 potent, selective, reversible and cell-permeable inhibitors, 1 potent, selective and reversible inhibitor, and 1 potent, selective, irreversible and cell-permeable inhibitor useful for the study of multiple signaling pathways activated by IGF: 1 mg of AG1024 (Cat. No. 121767); 1 mg of Akt Inhibitor IV (Cat. No. 124011); 1 mg of Akt Inhibitor VIII, Isozyme-Selective, Akti-1/2 (Cat. No. 124018); 1 mg of AMPK Inhibitor, Compound C (Cat. No. 171260); 10 mg of bpVphen (Cat. No. 203695); 1 mg of ERK Inhibitor, FR180204 (Cat. No. 328007); 5 mg of GSK-3β Inhibitor VIII (Cat. No. 361549); 1 mg of IGF-1R Inhibitor, PPP (Cat. No. 407247); 5 mg of NBI-31772 (Cat. No. 479830); 5 mg of PD 98059 (Cat. No. 513000); 1 mg of PI-103 (Cat. No. 528100); 500 µg of PKCβ Inhibitor (Cat. No. 539654); 100 µg of Rapamycin (Cat. No. 553210); 1 mg of RSK Inhibitor, SL0101 (Cat. No. 559285); 1 mg of ZM 336372 (Cat. No. 692000). Also provided with 15 ml of anhydrous DMSO (Cat. No. KP31817). Supplied with a data sheet.

Packaged under inert gas

Following reconstitution, aliquot and freeze (-20°C) each inhibitor. Each inhibitor solution is stable for up to 3 months at -20°C. Note: bpV(phen) (Cat. No. 203695) which is unstable in solution and should be reconstituted just prior to use.

Please refer to information provided on the CD for reconstitution information of individual inhibitors.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Toxicity: Regulatory Review (Z)